Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of the company's common stock, at a per share exercise price of $27.00, the closing tra...
Nov 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017. "We are thrilled that GOCOVRI (amantadine) extended release capsules is approved for Parkinson's disease patients with dyskinesia receiving l...
Nov 2, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report third quarter 2017 financial results on Thursday, November 2, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the ...
Oct 26, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Drug Products (OOPD) has recognized by letter to the company the seven-years of orphan drug exclusivity for GOCOVRI (amantadine) extended release capsules, the first and...
Oct 25, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. Ms. Dier will serve on the Audit Committee. Ms. Dier brings over 25 years of financial management experience in the ...
Oct 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted eleven new employees the option to purchase an aggregate of 78,750 shares of the company's common stock, at a per share exercise price of $23.11, the closing t...
Oct 6, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. - 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations...
Sep 13, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company's board of directors granted four new employees stock options to purchase an aggregate of 15,450 shares of the company's common stock, at a per share exercise price of $20.77, the closing...
Sep 11, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive topline data from the Phase 1b clinical trial of ADS-4101 (lacosamide) modified-release capsules. The study demonstrated that a 600 mg dose of ADS-4101, taken once-nightly, provided a 1.7-fold increase in average lacosamide c...
Sep 7, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with ...
Aug 24, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. "This is a very exciting time for Adamas, as we are potentially at the cusp of transitioning from a company focused on product development to a c...
Aug 8, 2017 General Releases HTML PDF
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the fi...
Aug 1, 2017 General Releases HTML PDF
EMERYVILLE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather. The compensation committee of the company's board of directors granted Mr. Merriweather a stock option to purchase 112,500 shares of the company'...
Jul 10, 2017 General Releases HTML PDF
EMERYVILLE, Calif, June 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Alfred G. Merriweather as Chief Financial Officer, reporting to Gregory T. Went, Ph.D., Chairman and Chief Executive Officer, and the retirement of William J. Dawson, its former Chief Financial Officer. Mr. Merriweath...
Jun 28, 2017 General Releases HTML PDF
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson's Disease Patients with Levodopa-induced Dyskinesia -- -- New Drug Application for ADS-5102 Currently Under FDA Review with August 24, 2017 PDUFA Date-- EMERYVILLE, Calif., June 12, 2017 (GLOBE NEWSWIRE...
Jun 12, 2017 General Releases HTML PDF
Page:
...
Next Last